Inventor · disambiguated record
Mika Sakurai
Also filed as: SAKURAI MIKA
10 granted patents·26 pending applications·207 citations·filing 2008–2025
90Inventor score
Top patents by PatentIndex Score
36 records- 0198US8562991B2Antibody molecules that bind to IL-6 receptorIGAWA TOMOYUKI·Filed 2009·Granted Oct 22, 2013·130 cites·19 claims
- 0296US10662245B2Methods of reducing IL-6 activity for disease treatmentCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted May 26, 2020·22 cites·25 claims
- 0395US11154615B2Library of antigen-binding molecules including modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Oct 26, 2021·8 cites·11 claims
- 0495US9975966B2Cytotoxicity-inducing theraputic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted May 22, 2018·25 cites·10 claims
- 0593US11001643B2Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted May 11, 2021·9 cites·34 claims
- 0693US2025101118A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0792US11739149B2Antigen-binding molecule containing modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Aug 29, 2023·5 cites·18 claims
- 0892US2025346677A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0991US12234573B2Library of antigen-binding molecules including modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Feb 25, 2025·1 cites·12 claims
- 1091US2024301075A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1188US11952422B2Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137CHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Apr 9, 2024·4 cites·15 claims
- 1288US2024010738A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1386US2023159648A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1485US12479916B2Antigen-binding molecule containing modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Granted Nov 25, 2025·0 cites·19 claims
- 1585US2025250362A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1683US12304960B2Anti-CD137 antigen-binding molecule and utilization thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted May 20, 2025·3 cites·27 claims
- 1783US2022306755A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1880US2022041741A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1974US2020231688A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2073US2021206862A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2172US2021230311A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2269US2025154689A1Library of Antigen-Binding Molecules Including Modified Antibody Variable RegionCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 2367US2024270846A1Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137CHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2466US2011245473A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 2563US2019085085A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 2663US2012253016A1Antibody molecules that bind to il-6 receptorIGAWA TOMOYUKI·Filed 2012·Application pending·0 cites
- 2762US2016280787A1Antigen-binding molecule containing modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
- 2862US2025388689A1Anti-cd137 antigen-binding molecule and utilization thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 2961US2013317203A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 3057US2017121412A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 3155US2023322898A1Pharmaceutical composition comprising cell expressing chimeric receptorCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3253US2022315909A1Protease substrate, and polypeptide including protease cleavage sequenceCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3352US2023272099A1Anti-cd137 antigen-binding molecule for use in cancer treatmentCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3452US2022324975A1Antibody cleavage site binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3551US2022143094A1Chimeric receptor that recognizes engineered site in antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3649US2022017585A1Cxcr3 ligandCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mika Sakurai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →